Conference Coverage

Tumor analysis: Test all MSI-high patients for Lynch Syndrome


 

REPORTING FROM ASCO 2018


She added that this is “a straightforward testing strategy which can be immediately implemented to impact not only the patients themselves and their risk of cancer, but also their family members and their risk of cancer.”

This study was funded by Romeo Milio Lynch Syndrome Foundation, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, the Robert and Kate Niehaus Center for Inherited Cancer Genomics, the Fieldstone Family Fund, Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant and the NIH/NCI Cancer Center Support Grant. Dr. Stadler reported consulting or advisory roles on the part of an immediate family member for Allergan, Genentech/Roche, Regeneron, Optos, and Adverum.

SOURCE: Schwark A et al., ASCO 2018 LBA1509.

Pages

Recommended Reading

Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis
MDedge ObGyn
‘Right to try’ bill passes House
MDedge ObGyn
Over one-third report financial burden from breast cancer treatment
MDedge ObGyn
Oncologist-led BRCA mutation testing and counseling may reduce wait times for women with ovarian cancer
MDedge ObGyn
Sarcopenia, body fat linked with mortality in nonmetastatic breast cancer
MDedge ObGyn
Hormone therapy raises diabetes risk in breast cancer survivors
MDedge ObGyn
Early breast cancer: Patients report favorable quality of life after partial breast irradiation
MDedge ObGyn
Reduced intensity conditioning doesn’t protect fertility
MDedge ObGyn
Breast cancer: More pathogenic variants detected as multiple-gene sequencing takes over
MDedge ObGyn
Ketorolac may reduce breast cancer recurrence risk, particularly in overweight patients
MDedge ObGyn